Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.

In a longitudinal study of the evolution of serum beta 2-microglobulin (beta 2-m) levels in 37 patients with myelomatosis, those patients with a level of < 4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of > mg/l had a median survival of 15...

Descripción completa

Detalles Bibliográficos
Autores principales: Norfolk, D., Child, J. A., Cooper, E. H., Kerruish, S., Ward, A. M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1980
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010446/
https://www.ncbi.nlm.nih.gov/pubmed/6159910
_version_ 1782136323698589696
author Norfolk, D.
Child, J. A.
Cooper, E. H.
Kerruish, S.
Ward, A. M.
author_facet Norfolk, D.
Child, J. A.
Cooper, E. H.
Kerruish, S.
Ward, A. M.
author_sort Norfolk, D.
collection PubMed
description In a longitudinal study of the evolution of serum beta 2-microglobulin (beta 2-m) levels in 37 patients with myelomatosis, those patients with a level of < 4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of > mg/l had a median survival of 15 months. THe beta 2-m appeared to be independent of the level of the paraprotein and its class, as seen in a vertical study of 129 patients. Analysis of the influence of a rising serum creatinine on the serum beta 2-m indicates that beta 2-m production is excessive in advanced disease with or without renal failure. Practical application of the measurement of serum beta 2-m in the stratification and monitoring of patients is suggested.
format Text
id pubmed-2010446
institution National Center for Biotechnology Information
language English
publishDate 1980
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20104462009-09-10 Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring. Norfolk, D. Child, J. A. Cooper, E. H. Kerruish, S. Ward, A. M. Br J Cancer Research Article In a longitudinal study of the evolution of serum beta 2-microglobulin (beta 2-m) levels in 37 patients with myelomatosis, those patients with a level of < 4 mg/l at first presentation had a median survival of 46 months, whereas those with an initial level of > mg/l had a median survival of 15 months. THe beta 2-m appeared to be independent of the level of the paraprotein and its class, as seen in a vertical study of 129 patients. Analysis of the influence of a rising serum creatinine on the serum beta 2-m indicates that beta 2-m production is excessive in advanced disease with or without renal failure. Practical application of the measurement of serum beta 2-m in the stratification and monitoring of patients is suggested. Nature Publishing Group 1980-10 /pmc/articles/PMC2010446/ /pubmed/6159910 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Norfolk, D.
Child, J. A.
Cooper, E. H.
Kerruish, S.
Ward, A. M.
Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
title Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
title_full Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
title_fullStr Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
title_full_unstemmed Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
title_short Serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
title_sort serum beta 2-microglobulin in myelomatosis: potential value in stratification and monitoring.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2010446/
https://www.ncbi.nlm.nih.gov/pubmed/6159910
work_keys_str_mv AT norfolkd serumbeta2microglobulininmyelomatosispotentialvalueinstratificationandmonitoring
AT childja serumbeta2microglobulininmyelomatosispotentialvalueinstratificationandmonitoring
AT coopereh serumbeta2microglobulininmyelomatosispotentialvalueinstratificationandmonitoring
AT kerruishs serumbeta2microglobulininmyelomatosispotentialvalueinstratificationandmonitoring
AT wardam serumbeta2microglobulininmyelomatosispotentialvalueinstratificationandmonitoring

Ejemplares similares